• Aziz, S.A., Davies, M., Pick, E., Zito, C., Camp, R.L., Rimm, D.L., Kluger, Y., and Kluger, H.M. (2009). Phospho-inositol-3 kinase (PI3K) as a therapeutic target in melanoma. Clin. Cancer Res. 15, 30293036.
  • Berger, A.J., Kluger, H.M., Li, N., Kielhorn, E., Halaban, R., Ronai, Z., and Rimm, D.L. (2003). Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. Cancer Res. 63, 81038107.
  • Berger, A.J., Camp, R.L., DiVito, K.A., Kluger, H.M., Halaban, R., and Rimm, D.L. (2004). Automated quantitative analysis of HDM2 expression in malignant melanoma shows association with early-stage disease and improved outcome. Cancer Res. 64, 87678772.
  • Berger, A.J., Davis, D.W., Tellez, C., Prieto, V.G., Gershenwald, J.E., Johnson, M.M., Rimm, D.L., and Bar-Eli, M. (2005). Automated quantitative analysis of activator protein-2alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction. Cancer Res. 65, 1118511192.
  • Chien, A.J., Moore, E.C., Lonsdorf, A.S., Kulikauskas, R.M., Rothberg, B.G., Berger, A.J., Major, M.B., Hwang, S.T., Rimm, D.L., and Moon, R.T. (2009). Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc. Natl. Acad. Sci. USA 106, 11931198.
  • DiVito, K.A., Berger, A.J., Camp, R.L., Dolled-Filhart, M., Rimm, D.L., and Kluger, H.M. (2004). Automated quantitative analysis of tissue microarrays reveals an association between high Bcl-2 expression and improved outcome in melanoma. Cancer Res. 64, 87738777.
  • Horst, B., Gruvberger-Saal, S.K., Hopkins, B.D. et al. (2009). Gab2-mediated signaling promotes melanoma metastasis. Am. J. Pathol. 174, 15241533.
  • Jilaveanu, L., Zito, C., Lee, S.J., Nathanson, K.L., Camp, R.L., Rimm, D.L., Flaherty, K.T., and Kluger, H.M. (2009). Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib. Clin. Cancer Res. 15, 10761085.
  • Kielhorn, E., Provost, E., Olsen, D., D’Aquila, T.G., Smith, B.L., Camp, R.L., and Rimm, D.L. (2003). Tissue microarray-based analysis shows phospho-beta-catenin expression in malignant melanoma is associated with poor outcome. Int. J. Cancer 103, 652656.
  • Kluger, H.M., DiVito, K., Berger, A.J., Halaban, R., Ariyan, S., Camp, R.L., and Rimm, D.L. (2004a). Her2/neu is not a commonly expressed therapeutic target in melanoma – a large cohort tissue microarray study. Melanoma Res. 14, 207210.
  • Kluger, H.M., DiVito, K., Berger, A.J., Ariyan, S., Halaban, R., Camp, R.L., and Rimm, D.L. (2004b). Her2/Neu is not a commonly expressed therapeutic target in malignant melanoma - a large cohort tissue microarray study. Melanoma Res. 14, 207210.
  • Kluger, H.M., McCarthy, M.M., Alvero, A.B., Sznol, M., Camp, R.L., Rimm, D.L., and Mor, G. (2007). The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by phenoxodiol is associated with carboplatin sensitization. J. Transl. Med. 5, 6.
  • McCarthy, M.M., DiVito, K.A., Sznol, M. et al. (2006). Expression of TRAIL receptors 1 and 2 in melanoma, Clin. Cancer Res. 12, 38563863.
  • Rothberg, B.E., Moeder, C.B., Kluger, H., Halaban, R., Elder, D.E., Murphy, G.F., Lazar, A., Prieto, V., Duncan, L.M., and Rimm, D.L. (2008). Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions. Mod. Pathol. 21, 11211129.
  • Rothberg, B.E., Berger, A.J., Molinaro, A.M., Subtil, A., Krauthammer, M.O., Camp, R.L., Bradley, W.R., Ariyan, S., Kluger, H.M., and Rimm, D.L. (2009). Melanoma prognostic model using tissue microarrays and genetic algorithms. J. Clin. Oncol. 27, 57725780.